Literature DB >> 4355137

Immunization of mice with live attenuated encephalomyocarditis virus: local immunity and survival.

W J Bogaerts.   

Abstract

Mice were vaccinated with an attenuated encephalomyocarditis (EMC) virus strain by the intraperitoneal (i.p.) route and by various ways of respiratory administration: aerosol exposure and intratracheal (i.t.) and intranasal (i.n.) instillation. A linear relationship was found between vaccine dose and the resulting serum antibody titer. The effectiveness of the vaccine was determined by measuring the 50% protective doses (ED(50) values) after a lethal challenge with live virulent virus given by the i.p. route. For all three methods of respiratory immunization essentially the same ED(50) value was found, about 200 plaqueforming units (PFU), but i.p. immunization was less effective, the ED(50) value being about 600 PFU. To investigate the protective effect of local immunity, mice were vaccinated i.p. or i.n. and challenged by the i.n. route. The same ED(50) values were found as after i.p. challenge, indicating that the degree of protection afforded by the vaccine depends only on the route of vaccination and not on the route of challenge. This means that protection depends largely on systemic immunity and that local immunity plays only a minor role in this system. The results are discussed in relation to the feasibility of respiratory immunization against animal viruses.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4355137      PMCID: PMC422886          DOI: 10.1128/iai.8.4.528-533.1973

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Comparison of protective effect of neutralizing antibody in serum and nasal secretions in experimental rhinovirus type 13 illness.

Authors:  J C Perkins; D N Tucker; H L Knopf; R P Wenzel; A Z Kapikian; R M Chanock
Journal:  Am J Epidemiol       Date:  1969-12       Impact factor: 4.897

2.  Control of acute mycoplasmal and viral respiratory tract disease.

Authors:  R M Chanock
Journal:  Science       Date:  1970-07-17       Impact factor: 47.728

3.  Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route.

Authors:  J C Perkins; D N Tucker; H L Knope; R P Wenzel; R B Hornick; A Z Kapikian; R M Chanock
Journal:  Am J Epidemiol       Date:  1969-10       Impact factor: 4.897

4.  The immunologic response of the mouse to aerosols of an attenuated encephalomyocarditis virus strain.

Authors:  C M Prato; T G Akers
Journal:  J Immunol       Date:  1969-07       Impact factor: 5.422

5.  Peroral infection and resistance to reinfection with encephalomyocarditis virus in the mouse.

Authors:  R Friedman; R M Maenza
Journal:  J Infect Dis       Date:  1968-04       Impact factor: 5.226

6.  [Immunogenic power by nasal route in hemagglutinizing subunits in mice of human influenza virus].

Authors:  J Cherby; G H Werner
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1968-09-23

7.  [Immunization of Papio papio monkeys by subcutaneous or respiratory route by means of hemagglutinating subunits of human grippe virus].

Authors:  J Cherby; G H Werner
Journal:  C R Acad Hebd Seances Acad Sci D       Date:  1969-05-28

8.  Neuraminidase- and hemagglutinin-inhibiting antibodies in serum and nasal secretions of volunteers immunized with attenuated and inactivated influenza B-Eng-13-65 virus vaccines.

Authors:  J C Downie
Journal:  J Immunol       Date:  1970-09       Impact factor: 5.422

9.  Antibody responses to and efficacy of an inactivated spray vaccine.

Authors:  A S Beare; D Hobson; S E Reed; D A Tyrrell
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

10.  Development of an attenuated mumps virus vaccine. II. Immune response of animals to vaccination with inactivated and live attenuated mumps viruses.

Authors:  G Shramek; F Deinhardt
Journal:  J Immunol       Date:  1969-04       Impact factor: 5.422

View more
  2 in total

1.  Prophylaxis and therapy of virulent encephalomyocarditis virus infection in mice by monoclonal antibodies. Brief report.

Authors:  F Vlaspolder; C A Kraaijeveld; R van Buuren; M Harmsen; B J Benaissa-Trouw; H Snippe
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

2.  Application of immunoassay of encephalomyocarditis virus in cell culture with enzyme-labeled virus-specific monoclonal antibodies for rapid detection of virus, neutralizing antibodies, and interferon.

Authors:  F Vlaspolder; T Harmsen; D van Veenendaal; C A Kraaijeveld; H Snippe
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.